|
|
|
| Efficacy and safety of atorvastatin plus low-molecular-weight dextran volume expansion in the treatment of acute cerebral infarction |
| FENG Xiaoli1 LI Jun1 JING Jing2 BIAN Keyu1▲ |
1.Department of Neurology, Wujin Hospital of Traditional Chinese Medicine, Jiangsu Province, Changzhou 213000, China;
2.Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100000, China |
|
|
|
|
Abstract Objective To investigate the efficacy and safety of atorvastatin plus low-molecular-weight dextran volume expansion in the treatment of acute cerebral infarction. Methods A total of 160 cases of acute cerebral infarction admitted to Wujin Hospital of Traditional Chinese Medicine in Changzhou from February 2018 to February 2022 were selected and they were divided into study group and control group by random number table method, with 80 cases in each group. The control group received routine treatment and Atorvastatin Calcium treatment, while the study group received low-molecular-weight dextran volume expansion treatment. After one week of treatment, patients of both groups were evaluated for efficacy, serum interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were compared between the two groups, and activities of daily life (ADL), Barthel index (BI), and Montreal cognitive assessment (MOCA) scores of cognitive function were compared between the two groups. Results The clinical efficacy of the study group was better than that of the control group, and the difference was statistically significant (P＜0.05). After one week of treatment, the levels of TNF-α and IL-6 in two groups were lower than those before treatment, and the study group was lower than control group, the differences were statistically significant (P＜0.05). After one week of treatment, MOCA, ADL, and BI scores in two groups were higher than those before treatment, and the study group was higher than control group, the differences were statistically significant (P＜0.05). There was no significant difference in the total incidence of adverse reactions between two groups (P＞0.05). Conclusion The intensive treatment of low-molecular-weight dextran volume expansion for acute cerebral infarction is helpful to promote the rapid recovery of patients, reduce the level of inflammation, improve cognitive function, improve the quality of life, and reduce the incidence of adverse reactions.
|
|
|
|
|
|
[1] 王月娟，冯士轩，胡瑾，等.丁苯酞联合阿托伐他汀钙对急性脑梗死患者血清炎性因子及脑神经递质的影响[J].实用医院临床杂志，2021，18（1）：23-26.
[2] 孙海燕，王云成，田晶.不同剂量阿托伐他汀对伴2型糖尿病急性脑梗死患者预后的影响[J].中国老年学杂志，2022，42（5）：1065-1068.
[3] 罗力亚，刘翠青，耿丽洁，等.不同剂量阿托伐他汀对高龄急性脑梗死患者血管内皮功能的影响[J].实用临床医药杂志，2021，25（16）：103-106，111.
[4] 刘彬，苏海龙.阿托伐他汀长期强化治疗对首诊冠心病患者血脂及炎症指标的影响[J].重庆医学，2022，51（16）：2755-2761.
[5] 丁妹，曹志勇，李胜利，等.不同炎症反应在脑梗死与短暂性脑缺血发作患者中表达及意义研究[J].国际神经病学神经外科学杂志，2017，44（3）：280-284.
[6] 马骊珠，乔亚光.复方血栓通胶囊结合阿托伐他汀片对急性脑梗死认知功能和血脂指标的影响[J].中华中医药学刊，2022，40（2）：227-230.
[7] 蔡智立，何奕涛，付学军，等.不同病因急性脑梗死患者静脉溶栓治疗的疗效分析[J].中国卒中杂志，2020，15（5）：504-509.
[8] 庄献博，徐光军，王未飞，等.阿托伐他汀对急性脑梗死患者外周血辅助性T细胞17及调节性T细胞平衡的影响[J].中华老年心脑血管病杂志，2019，17（10）：1096-1099.
[9] 余成，张红，洪萍，等.阿托伐他汀及免疫球蛋白联合应用对慢性心力衰竭患者免疫调节和炎性反应的影响[J].中国心血管病研究，2019，13（1）：43-46.
[10] Youssef S，Stüve O，Patarroyo JC，et al. The HMG-CoA reductase inhibitor，atorvastatin，promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease [J]. Nature，2002，420（6911）：78-84.
[11] 徐健强，赵国军，王燕，等.阿托伐他汀的抗炎作用及其机制的研究进展[J].中国动脉硬化杂志，2019，24（4）：419-423.
[12] 杨伟毅，邹慧莉，胡晓辉.依达拉奉联合阿托伐他汀钙治疗缺血性脑卒中的疗效[J].血栓与止血学，2020，23（6）：436-438.
[13] 刘新峰，孙文，朱武生，等.中国急性缺血性脑卒中早期血管内介入诊疗指南2018[J].中华神经科杂志，2019， 51（9）：683-691.
[14] 霍俊婷，王墨力，宋立刚.不同阿托伐他汀方案对大脑中动脉支架植入治疗急性脑梗死病人血流动力学、脑血管事件发生率的影响[J].中西医结合心脑血管病杂志，2020，18（20）：3471-3474.
[15] 张磊，刘建民.美国国立卫生研究院卒中量表[J].中华神经外科杂志，2014，52（15）：14.
[16] 巫嘉陵.日常生活能力量表（ADL）[J].中国微侵袭神经外科杂志，2006，11（11）：516.
[17] 李小峰，陈敏.改良Barthel指数评定量表的设计与应用[J].护理研究，2015，29（13）：1657-1658.
[18] 许贤平，黄春，易飞.尤瑞克林联合低分子右旋糖酐治疗急性脑梗死的随机对照研究[J].卒中与神经疾病，2019，21（4）：227-228.
[19] 王晓娟，赵臻.阿托伐他汀联合氯吡格雷对脑血栓患者的疗效及凝血功能，血液流变学的影响[J].血栓与止血学，2021，37（22）：53-54，57.
[20] 李胜愉，杨盛贤，曾爱苹，等.大剂量阿托伐他汀联合阿替普酶对急性脑梗死患者血清炎症因子及认知功能的影响[J].中国医院用药评价与分析，2021，21（7）：816- 819，825.
[21] 刘洋，郭艳丽.阿托伐他汀联合阿替普酶治疗急性脑梗死疗效研究[J].重庆医学，2020，49（2）：60-62.
[22] 安学雷，邵宇飞，张庆博，等.灯盏花素注射液结合阿托伐他汀对急性脑梗死5-HT、DA水平的影响[J].中华中医药学刊，2021，39（9）：233-236.
[23] 何志芳，姜亦伦.阿托伐他汀联合氯吡格雷治疗老年急性脑梗死的临床研究[J].国际老年医学杂志，2020，41（3）：161-164.
[24] 王少颖，王莉迪，李净兵，等.己酮可可碱缓释片联合阿托伐他汀治疗非痴呆老年脑小血管病的临床研究[J].临床和实验医学杂志，2022，21（20）：2140-2145.
[25] 刘全芳.曲美他嗪联合阿托伐他汀钙治疗冠心病心绞痛伴血脂异常的效果研究[J].中国医药科学，2022，12（3）：106-109.
[26] 王娜，罗文才，曹蒙.不同剂量阿托伐他汀钙对急性脑梗死微出血病人Hcy，Lp（a）水平的影响[J].贵州医药，2020，44（11）：1748-1749.
[27] 李建桥.阿托伐他汀钙片强化降脂对缺血性脑卒中患者血脂水平和颈动脉粥样硬化斑块的影响研究[J].中国全科医学，2020，23（S2）：194-196.
[28] 李健，周鑫玲，王治校，等.脂必泰联合低剂量阿托伐他汀钙治疗高龄高脂血症患者的临床效果[J].中国医药导报，2022，19（13）：161-164. |
|
|
|
